Increasing prevalence of extended-spectrum-betalactamase among Gram-negative bacilli in Latin America – 2008 update from the Study for Monitoring Antimicrobial Resistance Trends (SMART)

Rossi, 2006, In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 Study for Monitoring Antimicrobial Resistance Trends (SMART), J Antimicrob Chemother, 58, 205, 10.1093/jac/dkl199

Falagas, 2009, Extended-spectrum betalactamase- producing organisms, J Hosp Infect, 73, 345, 10.1016/j.jhin.2009.02.021

Paterson, 2006, Resistance in Gram-negative bacteria: Enterobacteriaceae, Am J Infect Control, 34, S20, 10.1016/j.ajic.2006.05.238

Carmeli, 2008, Strategies for managing today's infections, Clin Microbiol Infect, 14, 22, 10.1111/j.1469-0691.2008.01957.x

Green, 2005, Selection of an empiric antibiotic regimen for hospital- acquired pneumonia using a unit and culture-type specific antibiogram, J Intensive Care Med, 20, 296, 10.1177/0885066605278650

Villegas, 2008, Prevalence of extended spectrum beta-lactamases (ESBLs) in Europe and in the rest of the world: differences and similarities with South America, Clin Microbiol Infect, 14, 154, 10.1111/j.1469-0691.2007.01869.x

Paterson, 2005, In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART), J Antimicrob Chemother, 55, 965, 10.1093/jac/dki117

Chow, 2006, In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART), Surg Infect, 6, 439, 10.1089/sur.2005.6.439

Sader, 2000, Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98), Braz J Infect Dis, 4, 245

Reinert, 2007, Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline, J Antimicrobial Chemother, 60, 1018, 10.1093/jac/dkm310

Turner, 2005, (2005). Extended-Spectrum Beta-Lactamases, Clin Infect Dis, 41, S273, 10.1086/430789

Nogueira Kda, 2006, Occurrence of extended-spectrum beta-lactamases in Enterobacteriaceae isolated from hospitalized patients in Curitiba, southern Brazil, Braz J Infect Dis, 10, 390

Villegas, 2004, Prevalence and characterization of ESBLs from E. coli and K. pneumoniae isolates in Colombian hospitals, Diag Micro Infect Dis, 49, 217, 10.1016/j.diagmicrobio.2004.03.001

Biedenbach, 2004, Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002), Diagn Microbiol Infect Dis, 50, 59, 10.1016/j.diagmicrobio.2004.05.003

Peña, 2008, Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality, J Hosp Infect, 68, 116, 10.1016/j.jhin.2007.11.012

Paterson, 2004, “Collateral damage” from cephalosporin or quinolone antibiotic therapy, Clin Infect Dis, 38, S341, 10.1086/382690

Mosqueda-Gómez, 2008, Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamaseproducing Klebsiella pneumoniae: A case-control study, Int J Infect Dis, 12, 653, 10.1016/j.ijid.2008.03.008